Contents
Executive summary
Chimeric Antigen Receptors (CAR) – Background
Cancer Immunotherapy
Adoptive T cell therapy – T cells
Categories of adoptive T cell therapies
Adoptive T cell therapy – TIL approach
Adoptive T cell therapy – Genetically modified T cell approach
Adoptive T cell therapy – Genetically modified T cell approach – Engineered T cell receptor
Adoptive T cell therapy – Genetically modified T cell approach – Chimeric Antigen Receptor T cells (CAR-T)
Adoptive T cell therapy – Antigen selection for a CAR-T approach
CAR-T cell therapy – Potential issues and challenges
Chimeric Antigen Receptor T cells (CAR-T) – Review of Key Successful Clinical Trials
CAR-T cell therapy – successful clinical trials for CD19-CAR-T targeting acute lymphoblastic leukaemia
CAR-T cell therapy – successful clinical trials for CD19-CAR-T targeting lymphoma
Chimeric Antigen Receptors (CAR) – Current R&D pipeline
CAR-T Therapy – pipeline analysis methodology
Chimeric Antigen Receptor (CAR) Trials: total number of clinical trials
Chimeric Antigen Receptor (CAR) Trials: activity 2008-present
Chimeric Antigen Receptor (CAR) Trials: activity (industry)
Chimeric Antigen Receptor (CAR) Trials: activity (non industry)
Chimeric Antigen Receptor (CAR) Trials: phases and sponsor type
Chimeric Antigen Receptor (CAR) Trials: target indications (all phases)
Chimeric Antigen Receptor (CAR) Trials: phase I-IV, by indication
Chimeric Antigen Receptor (CAR) Trials: haematological indications, phases and sponsor type
Chimeric Antigen Receptor (CAR) Trials: multiple indications – phases and sponsor type
Chimeric Antigen Receptor (CAR) Trials: neurological indications – phases and sponsor type
Chimeric Antigen Receptors (CAR) – Advanced Clinical Trials for Blood Cancer Targets: Leukaemia/Lymphoma/Myeloma
Chimeric Antigen Receptor (CAR) Trials – haematological cancer targets
Blood cancer targets for CAR-T therapy: Leukaemia (background)
Leukaemia: survival rates and treatment types
Blood cancer targets for CAR-T therapy: Lymphoma (background) and survival rates
Lymphoma: current treatments
Blood cancer targets for CAR-T therapy: Myeloma (background), survival rates and current treatments
Advanced Clinical Trials for Leukaemia/Lymphoma/Myeloma
Leukaemia/Lymphoma/Myeloma – Industry sponsored CAR-T studies
Chimeric Antigen Receptors (CAR) – In depth review of key industry sponsored programmes
3 Contents available on request
2 Presentation titles may apply to more than one slide
Cellular Biomedicine Group Ltd: C-CAR011
Celyad: NKR2
Juno Therapeutics Inc, Celgene Corporation: JCAR017
Juno Therapeutics Inc, Celgene Corporation: other CD19+ trials
Juno Therapeutics Inc: CAR-T trials for additional targets
Juno Therapeutics, Inc., MedImmune LLC: JCAR014
Takara Bio Inc
Kite Pharma: KTE-C19
Novartis: CTL019
Novartis: CD19 CAR-T Long Term Follow Up
Servier, Cellectis, Pfizer: UCART19
Cellectis: additional UCARTS
CAR-T - summary and conclusions
Bibliography
About VacZine Analytics
Disclaimer
Slide number = 99